Cargando…

Immunogenicity of two-dose and three-dose vaccination schedules with Sabin inactivated poliovirus vaccine in China: An open-label, randomized, controlled trial

BACKGROUND: We assessed immunogenicity of three-dose and two-dose immunization schedules with a Sabin-strain inactivated poliovirus vaccine (sIPV) produced by one Chinese vaccine manufacturer. METHODS: This was an open label, randomized, controlled trial conducted in 16 vaccination clinics in Shando...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Yamin, Xu, Qing, Jeyaseelan, Vishali, Ying, Zhifang, Mach, Ondrej, Sutter, Roland, Wen, Ning, Rodewald, Lance, Li, Changgui, Wang, Jie, Yuan, Hui, Yin, Zundong, Feng, Zijian, Xu, Aiqiang, An, Zhijie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8315596/
https://www.ncbi.nlm.nih.gov/pubmed/34327346
http://dx.doi.org/10.1016/j.lanwpc.2021.100133
_version_ 1783729749036630016
author Wang, Yamin
Xu, Qing
Jeyaseelan, Vishali
Ying, Zhifang
Mach, Ondrej
Sutter, Roland
Wen, Ning
Rodewald, Lance
Li, Changgui
Wang, Jie
Yuan, Hui
Yin, Zundong
Feng, Zijian
Xu, Aiqiang
An, Zhijie
author_facet Wang, Yamin
Xu, Qing
Jeyaseelan, Vishali
Ying, Zhifang
Mach, Ondrej
Sutter, Roland
Wen, Ning
Rodewald, Lance
Li, Changgui
Wang, Jie
Yuan, Hui
Yin, Zundong
Feng, Zijian
Xu, Aiqiang
An, Zhijie
author_sort Wang, Yamin
collection PubMed
description BACKGROUND: We assessed immunogenicity of three-dose and two-dose immunization schedules with a Sabin-strain inactivated poliovirus vaccine (sIPV) produced by one Chinese vaccine manufacturer. METHODS: This was an open label, randomized, controlled trial conducted in 16 vaccination clinics in Shandong province. Infants were allocated randomly to either a 3-dose study arm (sIPV administered at 2, 3, and 4 months of age) or a 2-dose arm (sIPV administered at 4 and 8–11 months of age). Poliovirus neutralizing antibodies were measured in sera collected prior to the first sIPV dose and one month after the last dose. FINDINGS: We enrolled 560 infants; 536 (95.7%) completed the study. Final seropositivity rates were >98% for all three serotypes in both study arms. There were no statistically significant differences in seropositivity between the 2-dose and the 3-dose schedule. Final median reciprocal titres of polio antibodies were high overall (>1:768 for all serotypes) and statistically significantly higher in 2-dose recipients compared with 3-dose recipients (p < 0.001). INTERPRETATION: This study offers evidence that two doses of sIPV administered at 4 and 8–11 months of age and three doses of sIPV administered at 2, 3, and 4 months of age both provide serological protection against poliomyelitis. Median reciprocal titres of polio antibodies were high overall, and were more related to the interval between doses than the number of doses, with the longer interval of the 2-dose schedule producing higher reciprocal titres than the shorter-interval 3-dose schedule. The protection provided by the 3-dose schedule is achieved earlier in life than the protection with the 2-dose schedule. Countries planning to use an IPV-only schedule in the post-eradication era can consider this 2-dose sIPV option as an immunogenic and dose-sparing strategy. FUNDING: World Health Organization (from a grant from International PolioPlus Committee, Rotary International, Evanston, IL, USA).
format Online
Article
Text
id pubmed-8315596
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-83155962021-07-28 Immunogenicity of two-dose and three-dose vaccination schedules with Sabin inactivated poliovirus vaccine in China: An open-label, randomized, controlled trial Wang, Yamin Xu, Qing Jeyaseelan, Vishali Ying, Zhifang Mach, Ondrej Sutter, Roland Wen, Ning Rodewald, Lance Li, Changgui Wang, Jie Yuan, Hui Yin, Zundong Feng, Zijian Xu, Aiqiang An, Zhijie Lancet Reg Health West Pac Research Paper BACKGROUND: We assessed immunogenicity of three-dose and two-dose immunization schedules with a Sabin-strain inactivated poliovirus vaccine (sIPV) produced by one Chinese vaccine manufacturer. METHODS: This was an open label, randomized, controlled trial conducted in 16 vaccination clinics in Shandong province. Infants were allocated randomly to either a 3-dose study arm (sIPV administered at 2, 3, and 4 months of age) or a 2-dose arm (sIPV administered at 4 and 8–11 months of age). Poliovirus neutralizing antibodies were measured in sera collected prior to the first sIPV dose and one month after the last dose. FINDINGS: We enrolled 560 infants; 536 (95.7%) completed the study. Final seropositivity rates were >98% for all three serotypes in both study arms. There were no statistically significant differences in seropositivity between the 2-dose and the 3-dose schedule. Final median reciprocal titres of polio antibodies were high overall (>1:768 for all serotypes) and statistically significantly higher in 2-dose recipients compared with 3-dose recipients (p < 0.001). INTERPRETATION: This study offers evidence that two doses of sIPV administered at 4 and 8–11 months of age and three doses of sIPV administered at 2, 3, and 4 months of age both provide serological protection against poliomyelitis. Median reciprocal titres of polio antibodies were high overall, and were more related to the interval between doses than the number of doses, with the longer interval of the 2-dose schedule producing higher reciprocal titres than the shorter-interval 3-dose schedule. The protection provided by the 3-dose schedule is achieved earlier in life than the protection with the 2-dose schedule. Countries planning to use an IPV-only schedule in the post-eradication era can consider this 2-dose sIPV option as an immunogenic and dose-sparing strategy. FUNDING: World Health Organization (from a grant from International PolioPlus Committee, Rotary International, Evanston, IL, USA). Elsevier 2021-04-16 /pmc/articles/PMC8315596/ /pubmed/34327346 http://dx.doi.org/10.1016/j.lanwpc.2021.100133 Text en © 2021 Published by Elsevier Ltd. https://creativecommons.org/licenses/by-nc-nd/3.0/igo/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/igo/).
spellingShingle Research Paper
Wang, Yamin
Xu, Qing
Jeyaseelan, Vishali
Ying, Zhifang
Mach, Ondrej
Sutter, Roland
Wen, Ning
Rodewald, Lance
Li, Changgui
Wang, Jie
Yuan, Hui
Yin, Zundong
Feng, Zijian
Xu, Aiqiang
An, Zhijie
Immunogenicity of two-dose and three-dose vaccination schedules with Sabin inactivated poliovirus vaccine in China: An open-label, randomized, controlled trial
title Immunogenicity of two-dose and three-dose vaccination schedules with Sabin inactivated poliovirus vaccine in China: An open-label, randomized, controlled trial
title_full Immunogenicity of two-dose and three-dose vaccination schedules with Sabin inactivated poliovirus vaccine in China: An open-label, randomized, controlled trial
title_fullStr Immunogenicity of two-dose and three-dose vaccination schedules with Sabin inactivated poliovirus vaccine in China: An open-label, randomized, controlled trial
title_full_unstemmed Immunogenicity of two-dose and three-dose vaccination schedules with Sabin inactivated poliovirus vaccine in China: An open-label, randomized, controlled trial
title_short Immunogenicity of two-dose and three-dose vaccination schedules with Sabin inactivated poliovirus vaccine in China: An open-label, randomized, controlled trial
title_sort immunogenicity of two-dose and three-dose vaccination schedules with sabin inactivated poliovirus vaccine in china: an open-label, randomized, controlled trial
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8315596/
https://www.ncbi.nlm.nih.gov/pubmed/34327346
http://dx.doi.org/10.1016/j.lanwpc.2021.100133
work_keys_str_mv AT wangyamin immunogenicityoftwodoseandthreedosevaccinationscheduleswithsabininactivatedpoliovirusvaccineinchinaanopenlabelrandomizedcontrolledtrial
AT xuqing immunogenicityoftwodoseandthreedosevaccinationscheduleswithsabininactivatedpoliovirusvaccineinchinaanopenlabelrandomizedcontrolledtrial
AT jeyaseelanvishali immunogenicityoftwodoseandthreedosevaccinationscheduleswithsabininactivatedpoliovirusvaccineinchinaanopenlabelrandomizedcontrolledtrial
AT yingzhifang immunogenicityoftwodoseandthreedosevaccinationscheduleswithsabininactivatedpoliovirusvaccineinchinaanopenlabelrandomizedcontrolledtrial
AT machondrej immunogenicityoftwodoseandthreedosevaccinationscheduleswithsabininactivatedpoliovirusvaccineinchinaanopenlabelrandomizedcontrolledtrial
AT sutterroland immunogenicityoftwodoseandthreedosevaccinationscheduleswithsabininactivatedpoliovirusvaccineinchinaanopenlabelrandomizedcontrolledtrial
AT wenning immunogenicityoftwodoseandthreedosevaccinationscheduleswithsabininactivatedpoliovirusvaccineinchinaanopenlabelrandomizedcontrolledtrial
AT rodewaldlance immunogenicityoftwodoseandthreedosevaccinationscheduleswithsabininactivatedpoliovirusvaccineinchinaanopenlabelrandomizedcontrolledtrial
AT lichanggui immunogenicityoftwodoseandthreedosevaccinationscheduleswithsabininactivatedpoliovirusvaccineinchinaanopenlabelrandomizedcontrolledtrial
AT wangjie immunogenicityoftwodoseandthreedosevaccinationscheduleswithsabininactivatedpoliovirusvaccineinchinaanopenlabelrandomizedcontrolledtrial
AT yuanhui immunogenicityoftwodoseandthreedosevaccinationscheduleswithsabininactivatedpoliovirusvaccineinchinaanopenlabelrandomizedcontrolledtrial
AT yinzundong immunogenicityoftwodoseandthreedosevaccinationscheduleswithsabininactivatedpoliovirusvaccineinchinaanopenlabelrandomizedcontrolledtrial
AT fengzijian immunogenicityoftwodoseandthreedosevaccinationscheduleswithsabininactivatedpoliovirusvaccineinchinaanopenlabelrandomizedcontrolledtrial
AT xuaiqiang immunogenicityoftwodoseandthreedosevaccinationscheduleswithsabininactivatedpoliovirusvaccineinchinaanopenlabelrandomizedcontrolledtrial
AT anzhijie immunogenicityoftwodoseandthreedosevaccinationscheduleswithsabininactivatedpoliovirusvaccineinchinaanopenlabelrandomizedcontrolledtrial